✦ LIBER ✦

Hepatitis C virus infection and antiviral treatment

✍ Scribed by Omata, Masao ;Yokosuka, Osamu ;Hosoda, Kazuhiko ;Kato, Naoya ;Ito, Yoshimi ;Ohto, Masao

Book ID: 105605408
Publisher: Springer-Verlag
Year: 1991
Tongue: English
Weight: 351 KB
Volume: 26
Category: Article
ISSN: 0435-1339
DOI: 10.1007/bf02779307

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Caspase activation is required for antiv

Caspase activation is required for antiviral treatment response in chronic hepatitis C virus infection

✍ Xandra Volkmann; Markus Cornberg; Heiner Wedemeyer; Frank Lehner; Michael P. Man 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB 👁 1 views

Only half of patients with chronic hepatitis C virus (HCV) infection and genotype-1 show a sustained antiviral response to the current antiviral therapy. The reason this treatment fails is unclear, and no reliable marker exists that predicts the treatment outcome. In the present study, we investigat

Antiviral Treatment of Chronic Hepatitis

Antiviral Treatment of Chronic Hepatitis B Virus Infection: Infectious Virus Cannot Be Detected in Patient Serum after Permanent Responses to Treatment

✍ George H. Scullard; Harry B. Greenberg; Joseph L. Smith; Peter B. Gregory; Thoma 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 784 KB

Fourteen chimpanzees were inoculated with pre- and posttreatment sera from seven patients with persistent hepatitis B virus infection and chronic hepatitis who had permanent responses of their infection to treatment with interferon and/or adenine arabinoside. Inoculation of pretreatment serum at a d

Antiviral treatment of chronic hepatitis

Antiviral treatment of chronic hepatitis B virus infection: Improvement in liver disease with interferon and adenine arabinoside

✍ George H. Scullard; Ljudevit L. Andres; Harry B. Greenberg; Joseph L. Smith; Vin 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 398 KB 👁 1 views

Twelve of 32 patients lost HBeAg and DNA polymerase from their serum after completing antiviral therapy with interferon and/or adenine arabinoside. Three lost serum HBsAg as well. Loss of corresponding viral markers from hepatic tissue was also seen. There was improvement in symptoms, hepatic tests,

Effects of interferon treatment on the a

Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b- and genotype 2c-infected patients

✍ G Missale; E Cariani; V Lamonaca; A Ravaggi; A Rossini; R Bertoni; M Houghton; Y 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 219 KB 👁 3 views

The viral genotype may influence the response to interferon sion and more efficient antiviral immune response, is still (IFN) treatment in chronic hepatitis C virus (HCV) infection. unclear. To characterize potential mechanisms responsible for this ef-Several factors including viral load, disease se

Variants in interferon-alpha pathway gen

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial

✍ Tania Mara Welzel; Timothy R. Morgan; Herbert L. Bonkovsky; Deepa Naishadham; Ru 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 2 views

Combination treatment with pegylated-interferon-alpha (PEG IFN-␣) and ribavirin, the current recommended therapy for chronic hepatitis C virus (HCV) infection, results in a sustained virological response (SVR) in only about half of patients. Because genes involved in the interferon-alpha pathway may

Determinants of relapse after a short (1

Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection

✍ Alessandra Mangia; Nicola Minerva; Donato Bacca; Raffaele Cozzolongo; Ernesto Ag 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 142 KB 👁 2 views

In hepatitis C virus (HCV) genotypes 2 and 3 patients, the high rate of relapse after 12 to 16 weeks of antiviral therapy is the main concern for shortening treatment duration. This study was undertaken to delineate predictors of relapse after short treatment in patients with undetectable HCV RNA at